Tag Archives: formulation

Lack of Australian reformulation: Local governments have failed to promote healthier food choices | Instant News

The study was conducted by the University of Sydney and Deakin University, and involved analysis of food and nutrition policies carried out in six different local governments (LGs) in Australia (Blacktown, City of Sydney, Fairfield, Ku-Ring-Gai, Penrith, Randwick) comparing this with a model framework based on Australian literature and an international policy framework.

LGs are the third layer of government in Australia (under the federal government and state and territory governments). Regulatory bodies are generally called ‘councils’, whereas areas governed by LGs can range from cities to districts to districts. According to the Australian Bureau of Statistics, there are 562 Local Government Areas in Australia as of 2020.

The researchers found a lack of local government policies regulating healthier diets and nutrition, including in important areas such as reformulation of food products and unhealthy food marketing governance.

“We did not find any LGs involved in initiatives related to food processing and packaging, including policies on product reformulation targeted at food producers,”They said.

“In fact, our study found only one example of a specific policy on healthy eating / nutrition: Blacktown’s Access to the Fresh Food Policy, [but even this made no mention of any reformulation initiatives]. person

“We found only two mentions that encourage food retailers to increase the availability / affordability of healthy food, [but] not mentioned LGs are using food regulatory schemes to encourage retailers to improve food health. “ person


image source


12 October 2020 ASX Code: MXC

MGC Pharma shipped the first high THC formulation direct to

patients in Brazil through the ONIX online platform

Main Highlights:

  • MGC Pharma completes initial delivery of its Mercury Pharma line, which includes high THC products, direct to patients in Brazil through a supply and distribution agreement with ONIX
  • A major operational and commercial achievement as MGC Pharma is now the first company globally to ever supply high THC formulations directly to patients in Brazil under the country’s Compassionate Use Program.
  • Brazil is a market of strategic importance with a population of over 210 million1 people and pharmaceutical market value of ~ A $ 24 billion1 year
  • Potential to immediately develop new sales of materials and cash flow channels – new patients registering daily in Brazil for MGC Pharma products within weeks of first successful delivery
  • ONIX is actively recruiting doctors in Brazil and aims to have more than 1,000 doctors with the ability to prescribe cannabinoid products with mid-2021 – significantly broadens the market opportunities for MGC Pharma to supply its formulations

MGC Pharmaceuticals Ltd (ASX: MXC, ‘MGC Pharma’ or ‘Company’), a European based biopharma company that specializes in production and development phytocannabinoid derivativespharmaceuticals, is pleased to announce that it has completed the first shipment of its Pharmaceutical Mercury line which includes a high THC ratio product direct to patients in Brazil through binding supply and distribution agreements with Based in BrazilONIX Empreendimentos e Participações (‘ONIX’), (see ASX release March 3, 2020).

In a major operational milestone, MGC Pharma has become the first company globally to deliver high THC formulations directly to a patient’s door in Brazil, without the need to visit a pharmacy.

MGC Pharma has delivered Mercury Pharma (MP) branded products directly to patients according to the Brazilian Compassion Use Program after receiving the patient prescription given by the ONIX referral doctor. ONIX currently has more than 100 referral doctors in Brazil who can prescribe cannabinoid products under its Compassion Use Program and aims to have more than 300 referral doctors by the end of calendar 2020 and more than 1,000 by mid-2021. A complete line of Mercury Pharmaceuticals is now available. in Brazil which, based on the years experience of the Company’s medical team, covers a product range from pure CBD (MP100) through different ratios (1:30, 1: 1, 7: 1, 15: 1) to pure THC product MP252.

Brazil – Access to Large Target Markets Underway for MGC Pharma

The existing pharmaceutical drug market in Brazil represents a geography of strategic importance for MGC Pharmacy as Brazil has a population of more than 210 million people1. The National Health Expenditure in Brazil is estimated at A $ 267b1 with total expenditures on drugs estimated at A $ 24 billion1 every year. According to Interfarma (Pharmaceutical Research Industry Association), the Brazilian pharmaceutical market is expected to grow from A $ 59.9 billion in 2019 to A $ 66 billion in 2023.3 , through sales of approximately 238 million units3.

  1. Prohibition Partners, LATAM Cannabis Report, 2018
  2. View the Mercury Pharma Brochure via the Company’s website
  3. Interfarma 2019 Guide



In addition, there are 10,000 patients in Brazil who are currently registered with the Brazilian local authority, ANVISA, to receive cannabinoid products directly who are suffering from various medical conditions. Only 350 doctors out of more than 500,000 doctors across Brazil are currently authorized to prescribe cannabinoid products. This is expected to change due to the number of initiatives used by ONIX.


ONIX is a company based in Brazil that helps companies doing business in the region. It develops its business under the ONIXCANN brand and is a well-established distributor of phytocannabinoid-based products in Brazil that connects doctors and patients. ONIXCANN has an innovative digital and telemedicine platform called CANTERAMED which connects potential patients with relevant medical professionals. CANTERAMED is a complete digital wellness platform that facilitates safe and legal access to phytocannabinoid products and to guide doctors and patients about available treatments.

ONIX has established a partnership with one of the major Universities in Brazil, Anima Educação, and has developed a post-graduation course consisting of 12 nano degree courses of 30 hours each designed to train experienced doctors on CBD and THC products and authorize them to prescribe cannabinoid products.

ONIX has launched the second generation of CANTERAMED platform to help doctors better serve their patients. The CANTERAMED platform has facilitated doctors’ practice with its protocol for using MGC Pharma products and registering treatment results. CANTERAMED includes a telemedicine platform that connects patients with trained doctors to prescribe MGC Pharma products.

ONIX is currently also visiting doctors with a traditional pharmaceutical model who educates doctors about products and aims to have more than 1,000 doctors with the ability to prescribe cannabinoid products to patients by mid-2021.

This initiative is expected to continue to drive market awareness and penetration of cannabinoid products for eligible patients in Brazil.

Roby Zomer, Co-founder and Managing Director of MGC Pharma, comments: “I am very pleased to announce that we have successfully shipped our Mercury Pharma THC product range to Brazil. This is a great achievement as no other company has delivered high THC formulations directly to patients in Brazil before. We have worked closely with our Brazilian partner ONIX and remain confident that Brazil will become a very large strategic and commercially important region for us in the future. Feedback to date from patients in Brazil has been very positive and we see a rapidly increasing demand for our Mercury Pharmaceutical products. “

Marcelo Galvão, Founder of ONIX, comments: “We are very pleased to announce this. It has always been an important part of our strategy to bring high THC products to Brazil. There are more than 30,000 patients currently using homemade oils in Brazil and these patients are in desperate need of a quality product as we do now. take it with the Mercury Pharma Line. ”


Authorized for release by the Board, for more information please contact:

PR / IR advisor – Media & Capital Partners

MGC Pharmaceuticals Ltd.

Melissa Hamilton (PR) +61 417 750274

Roby Summer

Rod Hinchcliffe (IR) +61412277377

CEO & Managing Director

[email protected]

+61 8 6382 3390

[email protected]

[email protected]



About MGC Pharma

MGC Pharmaceuticals Ltd (ASX: MXC) is a European-based bio-pharmaceutical company that develops and supplies affordable standard phytocannabinoid-derived medicines to patients globally. The Company’s founders are key figures in the global medical cannabis industry and its core business strategy is to develop and supply high quality phytocannabinoid-derived pharmaceuticals for the growing demand in the medical market in Europe, North America and Australasia. MGC Pharma has a strong product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the path of development.

Using the ‘Nature to Medicine’ strategy, MGC Pharma has partnered with renowned institutions and academics to optimize the cultivation and development of targeted phytocannabinoid-derived medicinal products prior to production in the Company’s EU-GMP Certified manufacturing facilities.

MGC Pharma has a number of research collaborations with world-renowned academic institutions, and includes recent research highlighting the positive impact of using a specific phytocannabinoid formulation developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and thus far therapeutically resistant primary brain tumor.

MGC Pharma has a growing patient base in Australia, UK, Brazil and Ireland and has a global distribution footprint through an extensive network of commercial partners which means it is ready to supply the global market.

Follow us through our social media channels



This is an excerpt from the original content. To continue reading, access the original document here.


MGC Pharmaceuticals Ltd. publish this content on 11 October 2020 and take full responsibility for the information contained therein. Distributed by the Public, unedited and unaltered, at October 11 2020 21:54:08 UTC


image source

Return from travel to China – HAPPI | Instant News

Strict lockdown measures can do wonders in stemming a pandemic. This is the lesson to be learned from China, which saw a surge in travel during the all-important Golden Week, which celebrates the founding of the People’s Republic of China in 1949. The holidays have given a big boost to the trade of detail of the trip to China. It is estimated that nearly 640 million people traveled during the holiday week, which lasted a day longer than normal because Golden Week came right after the Mid-Autumn Festival. revelers spent $ 68.6 billion (466 billion renminbi) during the period, according to the China Tourism Research Institute. The total represents an increase of 79% and 69.9%, respectively, year over year at the two festivals. Meanwhile, several European countries face another round of lockdowns as the coronavirus returns to the continent. .

image source

The formulation of kiosk regulations is delayed due to lack of cooperation from MCI | Instant News

ISLAMABAD-Formulation of regulations for the designation of temporary kiosk sites in the spatial plan by the CDA is increasingly delayed due to the lack of cooperation from the Directorate of City Administration.

Regulations for allocating temporary kiosks / khokhasites in the spatial plan 2020 are placed before the CDA council in a meeting held in February this year. However, the board instead approved the same regulation which directed it to send it to the Islamabad Metropolitan Corporation (MCI) in advance for their inspection, evaluation and input. The CDA as a custodian of state land is mandated to allocate khoka sites through its planning wing while the MCI is permitted to distribute or issue licenses to individuals according to local government actions.

Although, Islamabad is the only planned city in Pakistan, unfortunately there are no formal regulations available to regulate dozens of stalls set up in the city on state land.

In the past, some khakis were approved by city managers while a large number of khakis operated without sanctions from the authorities as well. Those granted permission are also based on pick and choose because there are no laws in hand to distribute public land to private individuals for kiosks.

Now the authority has decided to bring this khokas into a framework and formulate these regulations but in addition to passing more than two months, the DMA response is still awaited.

When contacted, DMA Director ZafarIqbal had informed him that he had forwarded the file to the Mayor’s Office for approval and after that the same thing would be sent to the CDA Planning Wing.

“We don’t have a problem regarding the designation and site design designation by the CDA but we want some additional and further explanation on how to remove the site,” he said.

According to the destination regulation, the previous stalls will be deemed canceled as soon as the new regulation will be applied, the stalls will not be designated for Road Rights while no encroachment is permitted other than the agreed size. Pre-fabricated, de-mounted temporary structures will be permitted in accordance with designs approved by the CDA Architecture Directorate while there will be no permission to obtain gas and electricity connections and licensees will use solar energy, generators, gas cylinders etc. to meet their needs. The license will be responsible for keeping the area around the kiosk clean and green and it will not create environmental hazards. Stall land will remain the property of CDA and the site is temporarily non-transferable and no subletting is permitted.

The regulation also includes the use of kiosks that include tea and coffee shops, fast food and snack shops, grocery stores, fruit and vegetable shops, flower shops and newsstands and magazines.

According to regulations, the size of each kiosk site must be a maximum of 12 by 12 feet and planning members will be competent authorities to approve the designation and removal of the site. This site will be designated in undeveloped commercial areas, developing commercial areas, land that remains or is not used along service roads, highways, major city-level roads and near bus stops and metro stations. Regulations are being formed while following the direction of the Federal Minister for Domestic Brigadier Ijaz Shah who also chaired several meetings on this issue a few months ago.


image source